Sirolimus and pharmacotherapeutics for children with vascular anomalies：What we have known and what we have to know
Author:
Affiliation:
Fund Project:
摘要
|
图/表
|
访问统计
|
参考文献
|
相似文献
|
引证文献
|
资源附件
|
文章评论
摘要:
脉管异常性疾病，主要包括血管瘤和脉管畸形两大类，是儿童期常见疾病。哺乳动物雷帕霉素靶蛋白（mTOR）受体抑制剂西罗莫司（sirolimus）能够抑制细胞增殖和血管生成，有效治疗多个类型的脉管异常。随着国际脉管异常疾病研究学会（International Society for Study of Vascular Anomalies，ISSVA）分类在国内逐渐被认可和采纳，文章根据最新的分类系统就西罗莫司在儿童脉管异常性疾病中的应用情况进行介绍，旨在为西罗莫司给药方案提供参考。
Abstract:
Vascular anomalies are classified as vascular tumors and vascular malformation，common in childhood. The mammalian target of rapamycin inhibitor sirolimus has proved to be efficacious for many vascular anomalies by inhibiting cell proliferation and angiogenesis. Based on the latest International Society for Study of Vascular Anomalies （ISSVA） classification system，it was described the application of Sirolimus of vascular anomalies in children in this article. The purpose of this paper is to facilitate sirolimus precision dosing in children with vascular anomalies.
